CN105832701B - Aureomycin microcapsule premix and preparation method thereof - Google Patents
Aureomycin microcapsule premix and preparation method thereof Download PDFInfo
- Publication number
- CN105832701B CN105832701B CN201610313355.5A CN201610313355A CN105832701B CN 105832701 B CN105832701 B CN 105832701B CN 201610313355 A CN201610313355 A CN 201610313355A CN 105832701 B CN105832701 B CN 105832701B
- Authority
- CN
- China
- Prior art keywords
- parts
- aureomycin
- sucrose ester
- mixing agent
- cyst wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of feed additives, and particularly relates to a aureomycin microcapsule premix and a preparation method thereof, wherein the premix comprises the following raw materials, by weight, 15-30 parts of aureomycin hydrochloride, 10-24 parts of sucrose ester, 40-60 parts of a capsule wall polymer, 4-8 parts of xanthan gum, 8-12 parts of polyvinylpyrrolidone and 50-70 parts of water, wherein the sucrose ester comprises 5-12 parts of sucrose ester with an H L B value of 3-5 and 5-12 parts of sucrose ester with an H L B value of 12-14, and the capsule wall polymer comprises polylactic acid-glycolic acid copolymer and polyvinyl alcohol acetate phthalate in a weight ratio of (0.5-2) to (2-4).
Description
Technical field
The invention belongs to feed additive fields, and in particular to a kind of aureomycin micro-capsule pre-mixing agent and preparation method thereof.
Background technology
Aureomycin (Chlortetracycline), also known as duomycin, abbreviation CTC are first tetracyclines being found
Class antibiotic.Aureomycin has a broad antifungal spectrum, to gram-positive bacteria and negative bacterium, mycoplasma, Chlamydia, conveyor screw, Li Kecishi
Body, Amoeba etc. have inhibiting effect.The excellent antibiotic property of aureomycin is concerned in feed addictive.Feed grade gold
Mycin is aureomycin calcium salt, and aureomycin calcium salt itself does not have biological activity, is only changed under the action of animal hydrochloric acid in gastric juice
Hydrochloric acid aureomycin could be absorbed and utilized by animal body, but aureomycin hydrochloride is easy and the metal ion shape in gastrointestinal tract
At complex compound, and seriously affect the absorption of aureomycin.Physicochemical property shows that aureomycin calcium salt is metabolized rapidly in vivo, half-life period
It is shorter, it is generally suitable for part or digestion canal drug administration.In addition, aureomycin is unstable under acidic condition, it is easy to it hydrolyzes, and
Aureomycin bitter, palatability is poor, easily causes animal food refusal phenomenon, limits aureomycin to a certain extent and adds in feed
Add the application in agent field.
Therefore, in order to improve the utilization rate of aureomycin, improve the palatability of aureomycin, reduce gastric juice and aureomycin is broken
It is bad, so that aureomycin is discharged in enteron aisle, needs the preparation process for further increasing aureomycin horizontal.Chinese patent
201310015480.4 disclose a kind of Chlortetracycline microcapsule preparation and preparation method thereof, and said preparation includes aureomycin 17.5~35
Part, the methacrylic acid of weight ratio 1: 1 and copolymer 1 .6~4.8 part of methyl methacrylate, weight ratio 35: 65
2.5~7.5 parts of the copolymer of methacrylic acid and methyl methacrylate, 1.6 parts of microcrystalline cellulose and embedding medium 120~
140 parts.The aureomycin micro-capsule can make aureomycin dissolve out, destroy not in stomach and absorb, and make it in enteron aisle slow release, play and promote
The function of growth and health care.
Invention content
The purpose of the present invention is to provide a kind of aureomycin micro-capsule pre-mixing agents, to eliminate shadow of the aureomycin bitter to palatability
It rings, solves the problems, such as that aureomycin is unstable in gastric juice, facile hydrolysis, when extending useful effect of the aureomycin in enteron aisle
Between, reduce administration number of times.Invention also provides the preparation method of the aureomycin micro-capsule, microencapsulation skill of the present invention
Art is equally applicable to the preparation of other drugs microcapsule formulation.
The present invention is by following technical solution to realize above-mentioned purpose：
A kind of aureomycin micro-capsule pre-mixing agent includes the raw material of following parts by weight：15~30 parts of aureomycin hydrochloride, sucrose ester
50~70 parts of 10~24 parts, 40~60 parts of cyst wall polymer, 4~8 parts of xanthans, 8~12 parts of polyvinylpyrrolidone and water.
Further, the sucrose ester includes 5~12 parts of the sucrose ester that HLB value is 3~5 and the sugarcane that HLB value is 12~14
5~12 parts of sugar ester.
Preferably, the pre-mixing agent includes the raw material of following parts by weight：25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, capsule
60 parts of 50 parts of wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone and water.
Further, the cyst wall polymer is by Poly(D,L-lactide-co-glycolide and polyvinyl alcohol acetate phthalate
Ester is with (0.5~2): the weight ratio of (2~4) forms.
Preferably, the cyst wall polymer is by Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate
It is formed with 1: 2.5 weight ratio.
Further, the solvent of the cyst wall polymer is the organic solvent of readily volatilized removing, such as：Ethyl acetate or
Chlorinated organic solvent, the solvent can be dried and removed in micro-capsule preparation process by vacuum decompression, will not cause to remain.
Further, the solvent dosage of the cyst wall polymer is 1~2 times of cyst wall polymer weight.
In addition, the present invention also provides a kind of preparation methods of aureomycin micro-capsule pre-mixing agent comprising following steps：
(1) cyst wall polymer is taken, stirring solvent dissolving is added, and the sucrose ester that HLB value is 3~5 is added and is dispersed with stirring
It is even, obtain oil-phase solution；
(2) aureomycin hydrochloride is taken, the water of 1/3 amount is added, stirs evenly, is then dispersed in the oil-phase solution of step (1),
Form w/o type solution；
(3) take polyvinylpyrrolidone, be added the water of remaining 2/3 amount, stirring and dissolving, sequentially add HLB value for 12~
14 sucrose ester, xanthans, stirring are completely dissolved to material, obtain colloid aqueous solution；
(4) colloid aqueous solution of step (3) is added to while stirring in the w/o type solution of step (2), ultrasonic wave added point
1~3min is dissipated, stable W/O/W type multiphase emulsions are obtained；
(5) the W/O/W type multiphase emulsions of step (4) are subjected to vacuum decompression and dry 2~4h, obtain micro-capsule slurry, room temperature goes out
Material, 2500~3000r/min centrifuges 2~4min, then settled layer is washed with deionized 3~4 times, after decompression filters,
Be placed in vacuum belt drier dry 4~6h to get.
Further, step (5) the vacuum decompression drying parameter is：Heating temperature be 70 DEG C, vacuum degree be-
0.08MPa。
Further, step (5) the vacuum belt drier parameter is：Heat coolant-temperature gage proparea, middle area, back zone, cold
But area is respectively：120 DEG C, 110 DEG C, 90 DEG C, 30 DEG C, dry face temperature is 70 DEG C, and vacuum degree is 1200~1500Pa.
The present invention is prepared water-soluble with the sucrose ester blend that xanthans, polyvinylpyrrolidone and HLB value are 12~14
Liquid may advantageously facilitate w/o type lotion and disperse in water phase as colloid stabilizer, improves the stability of W/O/W multiphase emulsions, obtains
To the particle with regular spherical shape, and xanthans and polyvinylpyrrolidone have excellent film forming and high cohesive force,
Adhesion strength of the capsule material to drug can be improved, micro-crack occurs in micro-capsule surface when can also prevent dry.The xanthans is one
Kind boiomacromolecule polysaccharide, the side chain of main chain and oligosaccharide with cellulose stick in the range of pH value 1.5~13
Degree is unaffected, and therefore, when xanthans is when gastrointestinal tract is metabolized, multivalent metal salt can form gel with xanthans, from
And reduce aureomycin and form complex compound with metal ion, promote the absorption of aureomycin.The polyvinylpyrrolidone is a kind of non-
The high molecular weight water soluble polymer of ionic can form intermolecular association, to control drug with aureomycin hydrochloride
Release time and action intensity extend the release and absorption of drug in vivo, generate the effect of sustained release.
The preparation method of aureomycin micro-capsule pre-mixing agent of the present invention is equally applicable to feeding aureomycin or aureomycin hydrochloride and feeding
It is prepared with the microencapsulation of aureomycin mixture.
Compared with prior art, advantage of the invention is that：
(1) aureomycin micro-capsule pre-mixing agent of the present invention has the characteristics that enteric, sustained release, solves aureomycin in gastric juice
In unstable, facile hydrolysis the problem of, make aureomycin slow release in enteron aisle, extend useful effect of the aureomycin in enteron aisle
Time reduces administration number of times, moreover it is possible to reduce the influence that metal ion in the gastrointestinal tract absorbs aureomycin, improves gold
The bioavilability of mycin, and influence of the aureomycin bitter to palatability can be eliminated, improve feed intake.
(2) present invention prepares aureomycin micro-capsule with W/O/W multiphase emulsion methods, avoids mould using spray drying process preparation gold
When plain micro-capsule, aureomycin decomposes at high temperature, and drug effect reduces, while avoiding using coacervation easily by residual solvent and flocculating agent
Influence, and the sucrose ester blend aqueous solution by xanthans being added, polyvinylpyrrolidone and HLB value are 12~14 is used as
Colloid stabilizer may advantageously facilitate w/o type lotion and disperse in water phase, improves the stability of W/O/W multiphase emulsions, prevents emulsion droplet
Polymerization, obtains the microcapsule particle with regular spherical shape.
(3) aureomycin micro-capsule of the present invention has higher encapsulation rate, drugloading rate and lower burst release amount, microencapsulation
Improve the mobility and dispersibility of aureomycin, it is easier to be mixed with feed, use aureomycin micro-capsule pre-mixing agent of the present invention
The diarrhea rate of piglet can be significantly reduced, intestinal flora balance is improved, promotes piglet weightening, and the feed-weight ratio of piglet can be lowered, carries
The utilization rate of high feed, it is with obvious effects to be better than commercially available aureomycin micro-capsule pre-mixing agent.
Specific implementation mode
The present invention is further described below by way of specific implementation mode, but the present invention is not limited only to following embodiment.
Experimental example 1
The aureomycin micro-capsule pre-mixing agent of the embodiment of the present invention 1 includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone
With 60 parts of water；
Wherein, the sucrose ester includes 10 parts of the sucrose ester that HLB value is 4 and 6 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 1: 2.5 weight ratio；Institute
The solvent for stating cyst wall polymer is ethyl acetate, and the dosage of ethyl acetate is 1.5 times of cyst wall polymer weight；
Preparation method：
(1) cyst wall polymer is taken, ethyl acetate stirring and dissolving is added, and the sucrose ester that HLB value is 4 is added and is dispersed with stirring
It is even, obtain oil-phase solution；
(2) aureomycin hydrochloride is taken, the water of 1/3 amount is added, stirs evenly, is then dispersed in the oil-phase solution of step (1),
Form w/o type solution；
(3) polyvinylpyrrolidone is taken, the water of remaining 2/3 amount is added, stirring and dissolving, it is 12 to sequentially add HLB value
Sucrose ester, xanthans, stirring are completely dissolved to material, obtain colloid aqueous solution；
(4) colloid aqueous solution of step (3) is added to while stirring in the w/o type solution of step (2), ultrasonic wave added point
2min is dissipated, stable W/O/W type multiphase emulsions are obtained；
(5) the W/O/W type multiphase emulsions of step (4) are subjected to vacuum decompression drying, heating temperature is 70 DEG C, vacuum degree
For -0.08MPa, micro-capsule slurry is obtained after drying 4h, room temperature discharging, 2500r/min centrifuges 2min, then is washed with deionized
Settled layer 3 times is placed in vacuum belt drier, arrange parameter is after decompression filters：Heat coolant-temperature gage proparea, Zhong Qu, after
Area, cooling zone are respectively：120 DEG C, 110 DEG C, 90 DEG C, 30 DEG C, dry face temperature is 70 DEG C, and vacuum degree is 1200~1500Pa,
Dry 6h to obtain the final product.
Experimental example 2
The aureomycin micro-capsule pre-mixing agent of the embodiment of the present invention 2 includes the raw material of following parts by weight：
15 parts of aureomycin hydrochloride, 10 parts of sucrose ester, 40 parts of cyst wall polymer, 4 parts of xanthans, 8 parts of polyvinylpyrrolidone
With 50 parts of water；
Wherein, the sucrose ester includes 6 parts of the sucrose ester that HLB value is 4 and 4 parts of the sucrose ester that HLB value is 12；The cyst wall
Polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 1: 2.5 weight ratio；It is described
The solvent of cyst wall polymer is ethyl acetate, and the dosage of ethyl acetate is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1.
Experimental example 3
The aureomycin micro-capsule pre-mixing agent of the embodiment of the present invention 3 includes the raw material of following parts by weight：
30 parts of aureomycin hydrochloride, 24 parts of sucrose ester, 60 parts of cyst wall polymer, 8 parts of xanthans, 12 parts of polyvinylpyrrolidone
With 70 parts of water；
Wherein, the sucrose ester includes 14 parts of the sucrose ester that HLB value is 4 and 10 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 1: 2.5 weight ratio；Institute
The solvent for stating cyst wall polymer is ethyl acetate, and the dosage of ethyl acetate is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1.
Experimental example 4
The aureomycin micro-capsule pre-mixing agent of the embodiment of the present invention 4 includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone
With 60 parts of water；
Wherein, the sucrose ester includes 10 parts of the sucrose ester that HLB value is 4 and 6 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 0.5: 2 weight ratio；Institute
The solvent for stating cyst wall polymer is ethyl acetate, and the dosage of ethyl acetate is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1, difference lies in cyst wall polymer proportionings to form not with embodiment 1 for the present embodiment
Together.
Experimental example 5
The aureomycin micro-capsule pre-mixing agent of the embodiment of the present invention 5 includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone
With 60 parts of water；
Wherein, the sucrose ester includes 10 parts of the sucrose ester that HLB value is 4 and 6 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 1: 2 weight ratio；It is described
The solvent of cyst wall polymer is ethyl acetate, and the dosage of ethyl acetate is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1, difference lies in cyst wall polymer proportionings to form not with embodiment 1 for the present embodiment
Together.
Experimental example 6
The aureomycin micro-capsule pre-mixing agent of the embodiment of the present invention 6 includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone
With 60 parts of water；
Wherein, the sucrose ester includes 10 parts of the sucrose ester that HLB value is 4 and 6 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 1: 2.5 weight ratio；Institute
The solvent for stating cyst wall polymer is dichloroethanes, and the dosage of dichloroethanes is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1, the present embodiment are dichloro difference lies in the solvent of cyst wall polymer with embodiment 1
Ethane.
Comparative example 1
The aureomycin micro-capsule pre-mixing agent of comparative example 1 of the present invention includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of gelatin, 10 parts of polyvinylpyrrolidone and
60 parts of water；
Wherein, the sucrose ester includes 10 parts of the sucrose ester that HLB value is 4 and 6 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is made of Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with 1: 2.5 weight ratio；Institute
The solvent for stating cyst wall polymer is ethyl acetate, and the dosage of ethyl acetate is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1, difference lies in xanthans to be changed to gelatin with embodiment 1 for this comparative example.
Comparative example 2
The aureomycin micro-capsule pre-mixing agent of comparative example 2 of the present invention includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone
With 60 parts of water；
Wherein, the sucrose ester includes 10 parts of the sucrose ester that HLB value is 4 and 6 parts of the sucrose ester that HLB value is 12；The capsule
Wall polymer is polyvinyl alcohol phthalate；The solvent of the cyst wall polymer is ethyl acetate, the use of ethyl acetate
Amount is 1.5 times of cyst wall polymer weight；
Preparation method reference implementation example 1, this comparative example are polyvinyl alcohol second difference lies in cyst wall polymer with embodiment 1
Sour phthalic acid ester lacks Poly(D,L-lactide-co-glycolide.
The quality testing of test example one, aureomycin micro-capsule pre-mixing agent of the present invention
Quality requirement according to pharmacopeia about microcapsule formulation, to aureomycin made from 1-6 of the embodiment of the present invention and comparative example 1
Micro-capsule pre-mixing agent carries out appearance, grain size, encapsulation rate, drugloading rate and organic solvent residual inspection respectively, and to aureomycin micro-capsule into
Row tablets in vitro is tested, and 1 and table 2 are the results are shown in Table.
The quality examination result of 1 aureomycin micro-capsule pre-mixing agent of the present invention of table
The tablets in vitro test result of 2 aureomycin micro-capsule pre-mixing agent of the present invention of table
By upper table 1 it is found that aureomycin micro-capsule complete appearance made from 1-6 of the embodiment of the present invention, smooth, particle diameter distribution is 35
~65 μm, there is higher encapsulation rate and drugloading rate, and organic solvent residual limit test meets States Pharmacopoeia specifications.By embodiment 1-
3 it is found that best with aureomycin microencapsulation rate and drugloading rate made from 1 prescription of embodiment；Change the poly- breast in cyst wall polymer
The proportioning of acid-polyoxyethylene alcohol block copolymer and Poly(D,L-lactide-co-glycolide, can reduce the encapsulation rate of aureomycin micro-capsule
And drugloading rate, see embodiment 4 and 5.When the solvent of pocket wall polymer is changed to dichloroethanes by ethyl acetate, gold can be caused mould
Plain microcapsule diameter increases, and encapsulation rate and drugloading rate reduce, and see embodiment 6.When xanthans is changed to gelatin, cyst membrane can be caused to occur
A small amount of micro-crack, and encapsulation rate and drugloading rate reduction are more notable, see comparative example 1.When cyst wall polymer is polyvinyl alcohol acetic acid
Phthalic acid ester lacks Poly(D,L-lactide-co-glycolide, and aureomycin microencapsulation rate and drugloading rate can be caused to reduce, and sees pair
Ratio 2.The above result shows that it is best using aureomycin micro-capsule quality prepared by 1 prescription of embodiment, and xanthans and gelatin phase
Than there is more preferably colloidal stability, be conducive to micro-capsule molding, encapsulating and load medicine.
By upper table 2 it is found that aureomycin micro-capsule 2h in simulated gastric fluid made from 1-6 of the embodiment of the present invention and comparative example 1,2
Total release percentage it is relatively low, show aureomycin micro-capsule stomach release the drug it is less, have enteric characteristics；The aureomycin of gained is micro-
There is capsule 30min or so in simulated intestinal fluid burst effect, burst release amount to be below《Chinese Pharmacopoeia》Defined 40%；The gold of gained
The total release percentage that mycin micro-capsule total release percentage of 2h in simulated intestinal fluid reaches 50% or more, 6h reaches 80%
More than, and with the tablets in vitro best results of aureomycin micro-capsule made from embodiment 1, there is lower stomach release rate and burst release
Amount, higher enteron aisle release rate.When xanthans is changed to gelatin, the burst release of aureomycin micro-capsule 30min in simulated intestinal fluid can be caused
Amount increases, and sees comparative example 1；When cyst wall polymer is polyvinyl alcohol phthalate, shortage poly lactic-co-glycolic acid copolymerization
The burst effect of object, aureomycin micro-capsule becomes apparent, and sees comparative example 2, shows the slow releasing function of Poly(D,L-lactide-co-glycolide
Burst effect of the polyvinyl alcohol phthalate as cyst material 30min in simulated intestinal fluid is advantageously reduced, and
Be conducive to adjust rate of release of the aureomycin micro-capsule in enteron aisle.
The influence of test example two, aureomycin micro-capsule pre-mixing agent of the present invention to pig growth performance
1. test method
Piglet 160 similar in 80~100 age in days weight is screened, 4 groups, respectively control group, embodiment 1 are randomly divided into
1,2 group, every group 40 of group, comparative example.Wherein, control group mixed feed adds commercially available aureomycin micro-capsule pre-mixing agent (golden river biology
Science and Technology Co., Ltd.), 1 group of embodiment, comparative example 1 and 2 groups of mixed feeds add the embodiment of the present invention 1, comparative example 1 respectively
With 2 made from aureomycin micro-capsule pre-mixing agent, the additive amount of each group pre-mixing agent is 50g/1000kg (feed), and each group piglet is continuously raised
Feed 14d, weigh pig before the test, after weight, calculate feed-weight ratio, and record experiment during diarrhea rate (diarrhea rate=diarrhea
Piglet number × Diarrhoea days/(experiment piglet number × experiment number of days)).
2. result
The weight gain result of 3 each test group pig of table
| Group | Weight (kg) before experiment | (kg) is increased weight after experiment | Feed consumption/weightening | Diarrhea rate (%) |
| Control group | 28.12±4.38 | 5.20±1.16 | 2.85±0.82 | 3.25±0.76 |
| Embodiment 1 | 27.85±4.14 | 8.65±0.73* | 2.10±0.73 | 1.33±0.45* |
| Comparative example 1 | 27.90±4.25 | 8.32±0.65* | 2.24±0.75 | 1.52±0.26* |
| Comparative example 2 | 28.27±4.43 | 8.03±0.87 | 2.42±0.83 | 1.64±0.30* |
Note：Compared with the control group,*P ＜ 0.05.
3. conclusion
The present invention as a control group, investigates aureomycin micro-capsule premix provided by the invention with commercially available aureomycin micro-capsule pre-mixing agent
Influence of the agent to piglet growth performance, the results showed that, aureomycin micro-capsule pre-mixing agent provided by the invention can significantly reduce piglet
Diarrhea rate improves intestinal flora balance, promotes piglet weightening, and can lower the feed-weight ratio of piglet, improves the utilization rate of feed,
It is with obvious effects to be better than commercially available aureomycin micro-capsule pre-mixing agent.
It the above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
The limitation of the present invention, protection scope of the present invention should be subject to claim limited range.For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, several improvements and modifications can also be made, these change
Protection scope of the present invention is also should be regarded as into retouching.
Claims (8)
1. a kind of aureomycin micro-capsule pre-mixing agent, which is characterized in that the pre-mixing agent includes the raw material of following parts by weight：Hydrochloric acid gold
15 ~ 30 parts of mycin, 10 ~ 24 parts of sucrose ester, 40 ~ 60 parts of cyst wall polymer, 4 ~ 8 parts of xanthans, 8 ~ 12 parts of polyvinylpyrrolidone
With 50 ~ 70 parts of water；
The sucrose ester includes 5 ~ 12 parts of the sucrose ester that HLB value is 3 ~ 5 and 5 ~ 12 parts of the sucrose ester that HLB value is 12 ~ 14；
The cyst wall polymer is by Poly(D,L-lactide-co-glycolide and polyvinyl alcohol phthalate with (0.5 ~ 2):(2
~ 4) weight ratio composition.
2. pre-mixing agent according to claim 1, which is characterized in that the pre-mixing agent includes the raw material of following parts by weight：
25 parts of aureomycin hydrochloride, 16 parts of sucrose ester, 50 parts of cyst wall polymer, 6 parts of xanthans, 10 parts of polyvinylpyrrolidone and water 60
Part.
3. pre-mixing agent according to claim 1, which is characterized in that the cyst wall polymer is total to by poly lactic-co-glycolic acid
Polymers and polyvinyl alcohol phthalate are with 1:2.5 weight ratio composition.
4. pre-mixing agent according to claim 1, which is characterized in that the solvent of the cyst wall polymer is ethyl acetate or chlorine
Change organic solvent.
5. pre-mixing agent according to claim 4, which is characterized in that the solvent dosage of the cyst wall polymer polymerize for cyst wall
1 ~ 2 times of object weight.
6. a kind of method preparing pre-mixing agent according to any one of claims 1 to 5, which is characterized in that include the following steps：
（1）Cyst wall polymer is taken, stirring solvent dissolving is added, and the sucrose ester that HLB value is 3 ~ 5 is added and is dispersed with stirring uniformly, is obtained
Oil-phase solution；
（2）Aureomycin hydrochloride is taken, the water of 1/3 amount is added, stirs evenly, is then dispersed in step（1）Oil-phase solution in, formed
W/o type solution；
（3）Polyvinylpyrrolidone is taken, the water of remaining 2/3 amount is added, stirring and dissolving sequentially adds the sugarcane that HLB value is 12 ~ 14
Sugar ester, xanthans, stirring are completely dissolved to material, obtain colloid aqueous solution；
（4）By step（3）Colloid aqueous solution be added to step while stirring（2）W/o type solution in, ultrasonic wave added dispersion 1 ~
3min obtains stable W/O/W type multiphase emulsions；
（5）By step（4）W/O/W type multiphase emulsions carry out vacuum decompression and dry 2 ~ 4h, obtain micro-capsule slurry, room temperature discharging,
2500 ~ 3000r/min centrifuges 2 ~ 4min, then settled layer is washed with deionized 3 ~ 4 times, after decompression filters, is placed in true
In empty band drier dry 4 ~ 6h to get.
7. the preparation method of pre-mixing agent according to claim 6, which is characterized in that the step（5）Vacuum decompression drying ginseng
Number is：Heating temperature is 70 DEG C, and vacuum degree is -0.08MPa.
8. the preparation method of pre-mixing agent according to claim 6, which is characterized in that the step（5）Vacuum belt drier
Parameter is：Heating coolant-temperature gage proparea, middle area, back zone, cooling zone are respectively：120 DEG C, 110 DEG C, 90 DEG C, 30 DEG C, dry face temperature
It it is 70 DEG C, vacuum degree is 1200 ~ 1500Pa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610313355.5A CN105832701B (en) | 2016-05-11 | 2016-05-11 | Aureomycin microcapsule premix and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610313355.5A CN105832701B (en) | 2016-05-11 | 2016-05-11 | Aureomycin microcapsule premix and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105832701A CN105832701A (en) | 2016-08-10 |
| CN105832701B true CN105832701B (en) | 2018-09-14 |
Family
ID=56592259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610313355.5A Active CN105832701B (en) | 2016-05-11 | 2016-05-11 | Aureomycin microcapsule premix and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105832701B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106578839A (en) * | 2016-11-25 | 2017-04-26 | 广州市义和化工有限公司 | Feed mildew proofing agent and preparation method thereof |
| CN109528681B (en) * | 2018-12-12 | 2021-05-25 | 华南农业大学 | A chlortetracycline microcapsule granule for ruminant oral administration and its preparation method |
| CN113678837B (en) * | 2021-08-23 | 2022-12-02 | 王文明 | Plant extract slow-release insect-resist agent and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716092A (en) * | 2012-07-06 | 2012-10-10 | 浦城正大生化有限公司 | Formula of aureomycin hydrochloride premix granule and granulating process |
| CN103263400A (en) * | 2013-01-16 | 2013-08-28 | 内蒙古金河动物药业有限公司 | Chlortetracycline microcapsule preparation and preparation method thereof |
| CN103284956A (en) * | 2013-01-16 | 2013-09-11 | 内蒙古金河动物药业有限公司 | Chlortetracycline premix and preparation method thereof |
| CN103910586A (en) * | 2014-04-28 | 2014-07-09 | 成都新柯力化工科技有限公司 | Slow release fertilizer applicable to water-fertilizer integration and preparation method thereof |
-
2016
- 2016-05-11 CN CN201610313355.5A patent/CN105832701B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102716092A (en) * | 2012-07-06 | 2012-10-10 | 浦城正大生化有限公司 | Formula of aureomycin hydrochloride premix granule and granulating process |
| CN103263400A (en) * | 2013-01-16 | 2013-08-28 | 内蒙古金河动物药业有限公司 | Chlortetracycline microcapsule preparation and preparation method thereof |
| CN103284956A (en) * | 2013-01-16 | 2013-09-11 | 内蒙古金河动物药业有限公司 | Chlortetracycline premix and preparation method thereof |
| CN103910586A (en) * | 2014-04-28 | 2014-07-09 | 成都新柯力化工科技有限公司 | Slow release fertilizer applicable to water-fertilizer integration and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 微胶囊的制备方法研究进展;韩路路等;《生物质化学工程》;20110531;第45卷(第3期);第41-46页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105832701A (en) | 2016-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1890682B1 (en) | Use of polymer mixtures for the production of coated pharmaceutical formulations and pharmaceutical formulation with mixed polymeric coating | |
| US20150352214A1 (en) | Functional starch powder | |
| CN105832701B (en) | Aureomycin microcapsule premix and preparation method thereof | |
| CN102688195B (en) | Preparation method for doxorubicin hydrochloride-entrapped chitosan carboxymethyl chitosan nanometer controlled-release particle with pH sensibility | |
| CA2474691C (en) | Melt extrusion of salts of active ingredients | |
| US20140005280A1 (en) | Carboxymethyl starch and chitosan polyelectrolyte complexes | |
| CN103784396B (en) | Ibuprofen oral micropill xerogel and preparation method thereof | |
| CN104116721B (en) | A kind of Couoidal bismuth pectin capsules agent and preparation technology thereof | |
| CN105534950A (en) | Production method for kitasamycin solid micro-capsules for feed | |
| CN111110629A (en) | Curcumin multi-layer emulsion with colon-targeted delivery function and preparation method and application thereof | |
| Zeybek et al. | Designing robust xylan/chitosan composite shells around drug-loaded MSNs: Stability in upper GIT and degradation in the colon microbiota | |
| CN108837156A (en) | A kind of preparation method of carbon dots medicine-carried system | |
| Nayak et al. | Pharmaceutical applications of alginates | |
| Yang et al. | Preparation and antibacterial effect of potassium diformate hydrogel composites | |
| CN108653243B (en) | A kind of preparation method being sustained Tilmicosin microcapsule powder | |
| CN112494460B (en) | Tilmicosin powder and preparation method thereof | |
| CN105769786A (en) | Mirabegron sustained release tablet and preparation method thereof | |
| CN104306340B (en) | Slow controlled release microparticle of a kind of Allopurinol and preparation method thereof | |
| EP3892263A1 (en) | Oral dosage form | |
| EA038764B1 (en) | Smectite suspension liquid composition and method for preparing same | |
| CN105997894B (en) | Veterinary chlortetracycline premix and preparation method thereof | |
| CN106924198A (en) | Doxycycline hydrochloride oral disintegrating tablet for domestic fowls and preparation method thereof | |
| CN114106298B (en) | Ferulic acid lignin micro-nano particles capable of treating colonitis and preparation method thereof | |
| CN105902513A (en) | Enteric-coated aureomycin pellet premix and preparation method thereof | |
| CN110384708A (en) | A kind of mesalazine colon targeting controlled release tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160930 Address after: 510000 room 7E, No. five, No. 267, Tianhe District Road, Guangdong, Guangzhou Applicant after: GUANGZHOU YIHE CHEMICAL CO.,LTD. Address before: 510635 Guangdong city in Guangzhou province road five No. 267 Tianhe North Ruihua tower, 7 floor EF block Applicant before: Xu Huaiyi |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220505 Address after: 510000 No. 6 Huafeng Road, Yonghe District, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee after: GUANGZHOU CARDLO BIOCHEMICAL TECHNOLOGY Co.,Ltd. Address before: 510000 room 7e, No. 267, Wushan Road, Tianhe District, Guangzhou, Guangdong Patentee before: GUANGZHOU YIHE CHEMICAL CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510000 No. 6 Huafeng Road, Yonghe District, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee after: Guangdong Jiadele Technology Co.,Ltd. Address before: 510000 No. 6 Huafeng Road, Yonghe District, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee before: GUANGZHOU CARDLO BIOCHEMICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |